KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017)

Vertex Pharmaceuticals has reported Notes Payables over the past 2 years, most recently at $232.4 million for Q4 2017.

Quarterly results put Notes Payables at $232.4 million for Q4 2017, up 216.55% from a year ago — trailing twelve months through Dec 2017 was $232.4 million (up 216.55% YoY), and the annual figure for FY2017 was $232.4 million, up 216.55%.
Notes Payables for Q4 2017 was $232.4 million at Vertex Pharmaceuticals, up from $190.3 million in the prior quarter.
Over the last five years, Notes Payables for VRTX hit a ceiling of $232.4 million in Q4 2017 and a floor of $73.4 million in Q4 2016.